| UniProt ID | AP2B_HUMAN | |
|---|---|---|
| UniProt AC | Q92481 | |
| Protein Name | Transcription factor AP-2-beta | |
| Gene Name | TFAP2B | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 460 | |
| Subcellular Localization | Nucleus . | |
| Protein Description | Sequence-specific DNA-binding protein that interacts with inducible viral and cellular enhancer elements to regulate transcription of selected genes. AP-2 factors bind to the consensus sequence 5'-GCCNNNGGC-3' and activate genes involved in a large spectrum of important biological functions including proper eye, face, body wall, limb and neural tube development. They also suppress a number of genes including MCAM/MUC18, C/EBP alpha and MYC. AP-2-beta appears to be required for normal face and limb development and for proper terminal differentiation and function of renal tubular epithelia.. | |
| Protein Sequence | MHSPPRDQAAIMLWKLVENVKYEDIYEDRHDGVPSHSSRLSQLGSVSQGPYSSAPPLSHTPSSDFQPPYFPPPYQPLPYHQSQDPYSHVNDPYSLNPLHQPQQHPWGQRQRQEVGSEAGSLLPQPRAALPQLSGLDPRRDYHSVRRPDVLLHSAHHGLDAGMGDSLSLHGLGHPGMEDVQSVEDANNSGMNLLDQSVIKKVPVPPKSVTSLMMNKDGFLGGMSVNTGEVFCSVPGRLSLLSSTSKYKVTVGEVQRRLSPPECLNASLLGGVLRRAKSKNGGRSLRERLEKIGLNLPAGRRKAANVTLLTSLVEGEAVHLARDFGYICETEFPAKAVSEYLNRQHTDPSDLHSRKNMLLATKQLCKEFTDLLAQDRTPIGNSRPSPILEPGIQSCLTHFSLITHGFGAPAICAALTALQNYLTEALKGMDKMFLNNTTTNRHTSGEGPGSKTGDKEEKHRK | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 3 | Phosphorylation | -----MHSPPRDQAA -----CCCCHHHHHH | 34.99 | 101546443 | |
| 15 | Ubiquitination | QAAIMLWKLVENVKY HHHHHHHHHHHHCCH | 38.40 | - | |
| 21 | Sumoylation | WKLVENVKYEDIYED HHHHHHCCHHHHCCC | 55.28 | 12072434 | |
| 21 | Sumoylation | WKLVENVKYEDIYED HHHHHHCCHHHHCCC | 55.28 | - | |
| 26 | Phosphorylation | NVKYEDIYEDRHDGV HCCHHHHCCCCCCCC | 24.89 | 22817900 | |
| 92 | Ubiquitination | PYSHVNDPYSLNPLH CCCCCCCCCCCCCCC | 18.53 | 21963094 | |
| 94 | Ubiquitination | SHVNDPYSLNPLHQP CCCCCCCCCCCCCCC | 27.36 | 22817900 | |
| 120 | Phosphorylation | EVGSEAGSLLPQPRA HHHHHHHHCCCCHHH | 33.51 | 50565749 | |
| 223 | Phosphorylation | DGFLGGMSVNTGEVF CCCCCCEEECCCCEE | 18.58 | 20068231 | |
| 226 | Phosphorylation | LGGMSVNTGEVFCSV CCCEEECCCCEEEEC | 32.34 | 20068231 | |
| 232 | Phosphorylation | NTGEVFCSVPGRLSL CCCCEEEECCCCHHH | 21.63 | 20068231 | |
| 238 | Phosphorylation | CSVPGRLSLLSSTSK EECCCCHHHCCCCCC | 26.38 | 51163003 | |
| 241 | Phosphorylation | PGRLSLLSSTSKYKV CCCHHHCCCCCCEEE | 36.54 | 22617229 | |
| 242 | Phosphorylation | GRLSLLSSTSKYKVT CCHHHCCCCCCEEEE | 36.35 | 29255136 | |
| 243 | Phosphorylation | RLSLLSSTSKYKVTV CHHHCCCCCCEEEEH | 26.34 | 23663014 | |
| 244 | Phosphorylation | LSLLSSTSKYKVTVG HHHCCCCCCEEEEHH | 35.62 | 30576142 | |
| 245 | Ubiquitination | SLLSSTSKYKVTVGE HHCCCCCCEEEEHHH | 49.53 | 21963094 | |
| 246 | Phosphorylation | LLSSTSKYKVTVGEV HCCCCCCEEEEHHHH | 15.51 | 20068231 | |
| 247 | Ubiquitination | LSSTSKYKVTVGEVQ CCCCCCEEEEHHHHH | 34.86 | 22817900 | |
| 254 | Ubiquitination | KVTVGEVQRRLSPPE EEEHHHHHHHCCCHH | 22.07 | 21963094 | |
| 256 | Ubiquitination | TVGEVQRRLSPPECL EHHHHHHHCCCHHHH | 23.56 | 22817900 | |
| 258 | Phosphorylation | GEVQRRLSPPECLNA HHHHHHCCCHHHHCH | 36.28 | 24732914 | |
| 266 | Phosphorylation | PPECLNASLLGGVLR CHHHHCHHHHHHHHH | 24.05 | 24732914 | |
| 277 | Phosphorylation | GVLRRAKSKNGGRSL HHHHHHHHCCCCHHH | 30.30 | - | |
| 288 | Ubiquitination | GRSLRERLEKIGLNL CHHHHHHHHHHCCCC | 7.24 | 21963094 | |
| 290 | Ubiquitination | SLRERLEKIGLNLPA HHHHHHHHHCCCCCC | 46.82 | 22817900 | |
| 300 | Ubiquitination | LNLPAGRRKAANVTL CCCCCCCHHHCCCEE | 31.86 | 21963094 | |
| 301 | Ubiquitination | NLPAGRRKAANVTLL CCCCCCHHHCCCEEE | 50.95 | - | |
| 302 | Ubiquitination | LPAGRRKAANVTLLT CCCCCHHHCCCEEEE | 11.49 | 22817900 | |
| 354 | Ubiquitination | PSDLHSRKNMLLATK HHHHHHHHHHHHHHH | 50.12 | - | |
| 442 | Phosphorylation | NTTTNRHTSGEGPGS CCCCCCCCCCCCCCC | 34.88 | 27732954 | |
| 443 | Phosphorylation | TTTNRHTSGEGPGSK CCCCCCCCCCCCCCC | 28.81 | 27732954 |
| Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
|---|---|---|---|---|---|---|
| 258 | S | Phosphorylation | Kinase | PKA | - | Uniprot |
| Modified Location | Modified Residue | Modification | Function | Reference |
|---|---|---|---|---|
| 21 | K | Sumoylation |
| 12072434 |
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of AP2B_HUMAN !! | ||||||
| Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
|---|---|---|---|---|
| LZTR1_HUMAN | LZTR1 | physical | 20211142 | |
| SSBP4_HUMAN | SSBP4 | physical | 20211142 | |
| UBC9_HUMAN | UBE2I | physical | 12072434 | |
| YETS4_HUMAN | YEATS4 | physical | 16698963 | |
| CBP_HUMAN | CREBBP | physical | 25294805 |
| Kegg Disease | ||||||
|---|---|---|---|---|---|---|
| There are no disease associations of PTM sites. | ||||||
| OMIM Disease | ||||||
| 169100 | Char syndrome (CHAR) | |||||
| Kegg Drug | ||||||
| There are no disease associations of PTM sites. | ||||||
| DrugBank | ||||||
| There are no disease associations of PTM sites. | ||||||
loading...